CD33 and acute myeloid leukemia: One of these approaches consists of deleting CAR-T targets, like CLL-1 or CD33, with CRISPR/Cas9 from HSCs prior to transplant, thus avoiding off-tumor effects from CAR-T therapy and restricting the cytotoxic effect of CAR-T cells just to AML cells (Humbert et al., 2018; Kim et al., 2018; Xavier-Ferrucio et al., 2022).